TRIUMEQ Drug Patent Profile

« Back to Dashboard

Which patents cover Triumeq, and when can generic versions of Triumeq launch?

Triumeq is a drug marketed by Viiv Hlthcare and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in TRIUMEQ is abacavir sulfate; dolutegravir sodium; lamivudine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.

DrugPatentWatch^® Generic Entry Outlook for Triumeq

Triumeq was eligible for patent challenges on August 12, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.

There have been twenty-seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRIUMEQ

US Patents:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	20
Patent Applications:	239
Drug Prices:	Drug price information for TRIUMEQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIUMEQ
What excipients (inactive ingredients) are in TRIUMEQ?	TRIUMEQ excipients list
DailyMed Link:	TRIUMEQ at DailyMed

See drug prices for TRIUMEQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRIUMEQ

NDA:

205551

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRIUMEQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Macquarie University, Australia	PHASE3
Macquarie University, Australia	Phase 3
Stichting TRICALS Foundation	Phase 3

See all TRIUMEQ clinical trials

Pharmacology for TRIUMEQ

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Cytochrome P450 1A1 Inhibitors HIV Integrase Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors Organic Cation Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for TRIUMEQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIUMEQ	Tablets	abacavir sulfate; dolutegravir sodium; lamivudine	600 mg/50 mg/ 300 mg	205551	5	2017-08-14

US Patents and Regulatory Information for TRIUMEQ

TRIUMEQ is protected by two US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIUMEQ	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET;ORAL	205551-001	Aug 22, 2014		RX	Yes	Yes					Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes
Viiv Hlthcare	TRIUMEQ	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET;ORAL	205551-001	Aug 22, 2014		RX	Yes	Yes
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes

International Patents for TRIUMEQ

When does loss-of-exclusivity occur for TRIUMEQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Japan

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIUMEQ around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	300	Crystalline oxathiolane derivatives.
African Regional IP Organization (ARIPO)	9200395
Austria	212630
Australia	1736192

Supplementary Protection Certificates for TRIUMEQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1874117	C300676	Netherlands		PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, MET INBEGRIP VAN DOLUTEGRAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/13/892 20140121
1874117	CA 2014 00032	Denmark		PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140116
1874117	PA2014021	Lithuania		PRODUCT NAME: DOLUTEGRAVIRUM NATRICUM; REGISTRATION NO/DATE: EU/1/13/892/001, 2014 01 16 EU/1/13/892/002 20140116
1874117	1490036-9	Sweden		PRODUCT NAME: DOLUTEGRAVIR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT ELLER SOLVAT DAERAV, INKLUSIVE DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892 20140116

Triumeq Market Dynamics, Patent Exclusivity, Sales Decline, and Financial Outlook

Last updated: October 30, 2026

Triumeq is ViiV Healthcare’s fixed-dose, three-drug HIV treatment combining dolutegravir, abacavir, and lamivudine. The product generated substantial revenue after its 2014 U.S. launch, but sales are declining as treatment shifts toward two-drug regimens, long-acting injectables, and lower-cost generic components. Its commercial position remains defensible in selected patients, but the product is no longer a primary growth driver for ViiV.

What is Triumeq and how does it compete in HIV treatment?

Triumeq contains:

Component	Role
Dolutegravir	Integrase strand transfer inhibitor
Abacavir	Nucleoside reverse transcriptase inhibitor
Lamivudine	Nucleoside reverse transcriptase inhibitor

The tablet is indicated for treatment of HIV-1 infection in patients weighing at least 10 kilograms. It is not recommended for patients with the HLA-B*5701 allele because of the risk of potentially severe abacavir hypersensitivity reactions. The label also contains warnings concerning cardiovascular risk, lactic acidosis, hepatotoxicity, and immune reconstitution syndrome.[1]

Triumeq competed initially with Gilead’s Stribild and Atripla, as well as other once-daily combination products. Its current competitive set includes:

• Dovato, ViiV’s dolutegravir/lamivudine two-drug regimen
• Biktarvy, Gilead’s bictegravir/emtricitabine/tenofovir alafenamide product
• Juluca, ViiV’s dolutegravir/rilpivirine two-drug regimen
• Cabenuva, ViiV’s long-acting injectable cabotegravir/rilpivirine
• Generic abacavir, lamivudine, and dolutegravir products

The most important internal substitution is Dovato. Dovato removes abacavir from the regimen and has benefited from guideline movement toward two-drug treatment for appropriate patients.

How have Triumeq sales changed over time?

Triumeq sales have moved from launch growth to mature-product erosion. ViiV’s parent company, GSK, reports product sales in pounds sterling.

Fiscal year	Commercial position	Financial direction
2014	U.S. launch and rapid uptake	Initial growth
2015-2018	Broad adoption of dolutegravir-based therapy	Peak-growth period
2019-2021	Mature franchise with pressure from Biktarvy and Dovato	Decline begins
2022-2023	Increased switching to two-drug and newer integrase regimens	Continued decline
2024	Established product with generic and regimen-mix pressure	Material erosion

GSK reported Triumeq sales of approximately £1.5 billion in 2023, down from roughly £1.7 billion in 2022. The decline reflected lower demand in the United States and Europe, pricing pressure, and patients switching to Dovato and other products.[2] GSK’s 2024 reporting continued to identify Triumeq as a declining product within the HIV portfolio, while Dovato, Cabenuva, and newer long-acting products carried greater growth weight.[3]

Triumeq’s sales trajectory differs from ViiV’s overall HIV performance. ViiV has continued to grow through Cabenuva, Dovato, Tivicay, and expanded international access programs, while Triumeq has become a source of portfolio cannibalization and mature-brand decline.

What is the estimated revenue exposure?

Triumeq remains commercially relevant because its annual sales are still measured in the billion-pound range globally, but its contribution to ViiV’s growth is falling. The principal financial risks are:

1. Reduced new-patient starts.
2. Switching from three-drug to two-drug therapy.
3. Generic substitution for individual ingredients.
4. Tender and government pricing pressure.
5. Loss of premium positioning after patent and regulatory exclusivity expire.

The product’s revenue base is more exposed to volume erosion than to a sudden single-event collapse. HIV treatment decisions are controlled by formularies, clinical guidelines, patient history, resistance profiles, tolerability, and prescriber preference. Those factors usually produce a gradual decline rather than an immediate substitution event.

When does Triumeq lose exclusivity?

Triumeq’s regulatory exclusivity began with the approval of dolutegravir, the product’s novel active ingredient. The FDA approved Triumeq on August 22, 2014.[4]

The key U.S. exclusivity milestones are:

Exclusivity category	Relevant date or status
FDA approval	August 22, 2014
New chemical entity exclusivity for dolutegravir	Generally expired in 2019
Pediatric exclusivity	May extend applicable protection by six months where granted
Patent protection	Depends on Orange Book-listed patents, certifications, litigation, and product-specific claims
Generic entry	Determined by approved ANDAs, patent certifications, injunctions, and settlements

Regulatory exclusivity and patent exclusivity are separate. The end of five-year new chemical entity exclusivity did not automatically authorize unrestricted generic entry because patents could continue to block approval or launch.

The relevant protection is not limited to the Triumeq brand name. Potential generic exposure can arise through:

• A complete fixed-dose abacavir/dolutegravir/lamivudine product.
• Separate generic tablets prescribed together.
• Dolutegravir-containing combinations.
• Formulation or manufacturing claims.
• Patents covering the dolutegravir compound or pharmaceutical salts.

What patents protect Triumeq?

Triumeq is protected primarily through the dolutegravir patent estate and product-specific combination or formulation claims. Abacavir and lamivudine are older compounds whose basic compound patents are no longer the principal commercial barrier.

The patent analysis has four layers:

Patent layer	Commercial relevance
Dolutegravir compound patents	Protect the central integrase inhibitor
Salt, polymorph, and formulation patents	May affect specific dosage forms or manufacturing routes
Fixed-dose combination patents	May cover the three-drug tablet or its composition
Method-of-use patents	May cover treatment methods, dosing, or patient populations

The U.S. Orange Book should be used to determine the current listed patents for the approved Triumeq product and their expiration dates.[5] Patent listings can change through corrections, delistings, pediatric extensions, terminal disclaimers, and litigation outcomes. A patent that protects dolutegravir as a compound may not have the same scope as a patent directed to the finished Triumeq tablet.

How strong is the Triumeq patent estate?

The estate is stronger against a complete dolutegravir-based substitution than against use of the older NRTI components. Its commercial strength depends on whether a generic applicant must use the protected dolutegravir compound and whether the applicant can design around formulation or combination claims.

The estate is weaker in markets where:

• Dolutegravir compound protection has expired.
• Generic dolutegravir is approved.
• Abacavir and lamivudine are separately available.
• National patent enforcement is limited.
• Government procurement favors lowest-cost HIV regimens.

The estate is stronger in jurisdictions where later-expiring dolutegravir, formulation, or combination claims remain enforceable and where regulatory linkage delays approval.

What is the Orange Book status of Triumeq?

Triumeq is an FDA-approved prescription drug and is listed in FDA product databases. Its Orange Book status must be assessed at the product level, not solely by reviewing the patents for Tivicay, Dovato, or other dolutegravir products.[5]

The practical Orange Book questions are:

• Which patents are currently listed against Triumeq?
• Which patents have pediatric extensions?
• Are any patents subject to Paragraph IV litigation?
• Has an ANDA applicant received tentative or final approval?
• Does a settlement permit an earlier launch?
• Are listed patents directed to the product, its ingredients, or a method of use?

An ANDA applicant may submit a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or will not be infringed. The filing of a Paragraph IV notice can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval under the Hatch-Waxman framework.[6]

Which companies are challenging Triumeq exclusivity?

The generic challenge landscape is fragmented because companies can pursue either a complete fixed-dose combination or separate component products.

Potential challengers include generic manufacturers with established HIV portfolios, such as Teva, Viatris, Sandoz, Cipla, Aurobindo, Dr. Reddy’s, and Hetero. The existence of a generic version of one or more components does not establish approval of a substitutable Triumeq-equivalent product.

The most commercially important challenge scenarios are:

1. A complete generic abacavir/dolutegravir/lamivudine tablet.
2. Generic dolutegravir used with generic abacavir/lamivudine.
3. A licensed or authorized generic arrangement.
4. Earlier generic entry under a confidential or public settlement.
5. Regional entry outside the United States after local patent expiry.

No biosimilar pathway applies to Triumeq. It is a small-molecule fixed-dose tablet, so competition proceeds through generic drug pathways, not the FDA biosimilar framework.

What generic entry risks exist for Triumeq?

United States

U.S. generic risk is driven by Orange Book patents and the timing of ANDA litigation. A complete generic could materially reduce net pricing, but prescriber and payer substitution may be gradual because HIV regimens are not interchangeable in every patient.

Generic competition would affect Triumeq through:

• Lower reimbursement benchmarks.
• Formulary exclusion or step-edit requirements.
• Greater use of component-level substitution.
• Reduced patient switching into the branded product.
• Higher contracting pressure from public programs.

Europe

European exposure is country-specific. Patent expiry, supplementary protection certificates, national litigation, tender rules, and local reimbursement policies determine entry. The European market is particularly sensitive to centralized procurement and national health-system pricing.

Emerging markets

ViiV has used licensing and access agreements for antiretroviral medicines in low- and middle-income countries. Voluntary licensing through the Medicines Patent Pool has helped expand access to dolutegravir-based therapies, including pediatric and adult formulations.[7] This improves patient access but limits premium pricing in licensed territories.

What litigation and settlement agreements affect Triumeq?

The central legal risk is Paragraph IV litigation involving patents covering dolutegravir or the fixed-dose product. A lawsuit does not itself establish infringement or delay commercial entry permanently. The outcome depends on patent validity, claim construction, infringement, settlement terms, and FDA approval timing.

A settlement can produce several outcomes:

Settlement structure	Effect
Delayed authorized launch	Generic enters before full patent expiry but after a negotiated date
License with royalties	Generic launches under a license while preserving patent rights
No-admission settlement	Parties resolve litigation without a final validity ruling
Product-specific carve-out	Generic launches with a label excluding patented uses
Regional settlement	Entry timing differs by country

Publicly available litigation information should be checked through FDA records, PACER, district-court dockets, and GSK or ViiV disclosures. GSK’s annual reports identify material patent disputes and product risks but do not always provide complete commercial terms for confidential settlements.[2][3]

How does Triumeq compare with Dovato and Biktarvy?

Product	Company	Regimen	Commercial trajectory	Main advantage
Triumeq	ViiV Healthcare	Dolutegravir/abacavir/lamivudine	Declining	Established efficacy and once-daily dosing
Dovato	ViiV Healthcare	Dolutegravir/lamivudine	Growing or more resilient	Two-drug regimen and no abacavir
Biktarvy	Gilead	Bictegravir/emtricitabine/TAF	Strong commercial competitor	Broad use and strong prescriber familiarity
Cabenuva	ViiV Healthcare	Long-acting cabotegravir/rilpivirine	Growth product	Reduced daily pill burden
Juluca	ViiV Healthcare	Dolutegravir/rilpivirine	Mature niche product	Two-drug maintenance option

Triumeq is disadvantaged by abacavir-related cardiovascular and HLA-B*5701 considerations. Dovato has benefited from the clinical and commercial appeal of reducing the number of active agents. Biktarvy has captured treatment-naive and switch patients through broad formulary access and strong Gilead commercialization.

Triumeq retains value for patients with specific resistance histories, renal considerations, prior treatment experience, or clinical reasons supporting its established three-drug profile.

What is Triumeq’s manufacturing and intellectual-property risk?

Triumeq manufacturing depends on reliable supply of three active pharmaceutical ingredients and the ability to produce a stable fixed-dose tablet at commercial scale. The manufacturing barrier is lower than for biologic drugs or long-acting injectable products.

The principal barriers are:

• Dolutegravir API quality and supply.
• Fixed-dose tablet process validation.
• Bioequivalence requirements.
• Stability and impurity control.
• Regulatory filing requirements in each market.
• Patent claims covering salts, polymorphs, formulations, or manufacturing processes.

Manufacturing complexity is therefore a secondary barrier compared with patent and regulatory timing. Generic manufacturers with established antiretroviral facilities can potentially enter once legal and approval barriers are resolved.

What is Triumeq’s financial outlook?

Triumeq is likely to remain a significant cash-generating product, but its sales trajectory is structurally negative. The product is transitioning from a growth asset to a mature franchise contributor.

The financial outlook has four stages:

1. Continued erosion in new starts as Dovato, Biktarvy, and Cabenuva gain share.
2. Margin pressure from payer negotiations and generic components.
3. Accelerated decline after effective complete-product generic entry.
4. Residual demand from treatment-experienced patients and markets with slower substitution.

ViiV’s strategy is to replace declining Triumeq revenue with newer products rather than defend Triumeq through major lifecycle expansion. Cabenuva, Dovato, and long-acting pipeline programs are more important to the company’s forward growth profile.[3]

Key Takeaways

• Triumeq combines dolutegravir, abacavir, and lamivudine and was approved by the FDA in August 2014.
• Sales have declined from their peak as patients move to Dovato, Biktarvy, Cabenuva, and other newer regimens.
• The product remains a billion-pound-scale commercial asset, but it is no longer a major ViiV growth engine.
• Regulatory exclusivity has expired; remaining protection depends mainly on product-specific and dolutegravir-related patents.
• Generic risk is greater for the individual ingredients than for an immediately substitutable complete fixed-dose product.
• Triumeq has no biosimilar risk because it is a small-molecule tablet.
• U.S. entry timing depends on Orange Book patents, Paragraph IV certifications, litigation, FDA approval, and any settlement terms.
• The strongest long-term commercial risk is gradual regimen substitution followed by lower-cost generic competition.
• Manufacturing barriers are manageable for experienced antiretroviral manufacturers; patent and regulatory barriers are more important.
• ViiV’s financial strategy is to offset Triumeq erosion with Dovato, Cabenuva, Tivicay, and other next-generation HIV products.

FAQs

Is Triumeq still patent protected?

Patent protection may remain for dolutegravir-related, formulation, or combination claims even though FDA regulatory exclusivity has expired. The controlling analysis is the current FDA Orange Book listing and applicable court decisions.

Can generic abacavir and lamivudine replace Triumeq?

They can replace individual components in some treatment plans, but substitution requires clinical review. Generic component availability does not automatically create a therapeutically interchangeable Triumeq product.

Is Dovato replacing Triumeq?

Dovato is one of the main products taking share from Triumeq because it provides a two-drug dolutegravir-based regimen without abacavir. The degree of substitution depends on patient history, resistance, tolerability, and payer policy.

Does Triumeq have biosimilar competition?

No. Triumeq is a small-molecule fixed-dose combination, so competition occurs through generic drug applications rather than biosimilar applications.

What would cause the sharpest Triumeq revenue decline?

The largest single pressure would be approval and launch of a substitutable generic three-drug combination combined with broad payer substitution. Before that event, sales are more likely to decline gradually through treatment switching and component-level competition.

References

1. U.S. Food and Drug Administration. (2024). Triumeq prescribing information.
2. GSK plc. (2024). Annual report 2023.
3. GSK plc. (2025). Annual report 2024.
4. U.S. Food and Drug Administration. (2014, August 22). FDA approves Triumeq for HIV-1 infection.
5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417.
7. Medicines Patent Pool. (2024). License agreements and HIV medicines access programs.

DrugChatter Q&A for TRIUMEQ

Patent infringement triumeq?
Is there a generic version of triumeq from viiv healthcare?